Issues in planning and interpreting active control equivalence studies

Journal of Clinical Epidemiology

Volumn 42, Issue 6, 1989, Pages 503-511

  Makuch, Robert ^a,b   Johnson, Mary ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b G H Besselaar Associates   (United States)

Author keywords

Active control; Clinical trials methodology; Study design

Indexed keywords

CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; METHODOLOGY; PRIORITY JOURNAL; THEORETICAL STUDY;

ADULT; ASPIRIN; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS; COMPARATIVE STUDY; HUMAN; RANDOM ALLOCATION; RESEARCH DESIGN; SULFINPYRAZONE; SUPPORT, U.S. GOV'T, P.H.S.; TICLOPIDINE;

EID: 0024400492     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-4356(89)90146-7     Document Type: Article

References (53)

1. Randomized clinical trials
2. Non-randomized controls in cancer clinical trials
3. A new design for randomized clinical trials
4. Strategy and alternate randomized designs in cancer clinical trials
5. Clinical trial methodology
6. Designing and analyzing clinical trials which allow institution to randomize patients to a subset of the treatments under study
7. A note on the design of multi-institution three-treatment studies
8. Trimethoprim-sulfamethorazole or pentamidine for pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: A prospective randomized trial
9. Letter to the Editor
10. Letter to the Editor
11. Letter to the Editor
12. Some issues in the design and interpretation of “negative” clinical trials
13. Sample size requirements for evaluating a conservative therapy
14. Hospital discharge one week after acute myocardial infarction
15. Confidence intervals
16. Confidence intervals rather than P values: Estimation rather than hypothesis testing
17. Confidence intervals for reporting results of clinical trials
18. Statistical significance tests
19. Comparison of different methods for decision making in bioequivalence assessment
20. The use of confidence intervals in biopharmaceutics
21. Use of confidence intervals in analysis of comparative bioavailability trials
22. Symmetric confidence intervals for bioequivalence trials
23. Design and statistical evaluation of bioequivalence studies in man
24. “Providing the null hypothesis” in clinical trials
25. Sample size requirements for evaluating a conservative therapy
26. A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion
27. Explanatory and pragmatic attitudes in therapeutic trials
28. Significance testing to establish equivalence between treatments, with special reference in data in the form of 2 × 2 tables
29. A new statistical procedure for testing equivalence in two-group comparative bioavailability trials
30. A new procedure for testing equivalence in comparative bioavailability and other clinical trials
31. The qualification and disqualification of patients and events in long-term cardiovascular clinical trials
32. Controversy in counting and attributing events in clinical trials
33. The implicit assumptions of active control trials. Invited FDA Case Study
34. Government viewpoint of clinical trials
35. The North African Ticlopidine Aspirin Stroke Study: Structure, Stratification Variables, and Patient Characteristics
36. Controlled trial of aspirin in cerebral ischemia
37. A randomized trial of aspirin and sulfinpyrazone in threatened stroke
38. Aspirin in patients with cerebral ischemia and normal angiograms or nonsurgical lesions. Results of a double-blind trial
39. Controlled trial of aspirin in cerebral ischemia
40. Prevention ties recidives ties accidents vasculaires cerebraux ischemiques parles anti-agregants plaquettaires. Resultats d'un essai therapeutique controls de 3 ans
41. A randomized trial of aspirin and sulfinpyrazone in patients with TIA
42. “AICLA” Controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombitic cerebral ischemia
43. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish Cooperative Study
44. When was a “negative” clinical trial big enough? How many patients you needed depends on what you found
45. Editorial: Transient ischemic attacks and aspirin, stroke, and death; negative studies and Type II error
46. Integrating findings: the meta-analysis of research
47. Meta-analysis of randomized clinical trials
48. Secondary prevention of vascular disease by prolonged antiplatelet treatment
49. Anti-platelet agents in the secondary prevention of stroke: Meta-analysis of the randomized control trials
50. A simulated study of historical controls using real data
51. Randomized clinical trials (letter)
52. Generalized binomial models to examine the historical control assumption in active control equivalence studies.